Levofloxacin Tablet, Film Coated
NDC 76420-815
Product Information
Levofloxacin is a ANDA-approved product labeled by Asclemed Usa, Inc.. Levofloxacin is used to treat a variety of bacterial infections. It is supplied as a pink tablet, film coated for oral administration. This product entry covers the primary NDC 76420-815 and 10 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
13;T
Code Structure Chart
Product Details
What is NDC 76420-815?
What are the uses of this product?
What are Active Ingredients of this product?
- LEVOFLOXACIN 250 mg/1 - The L-isomer of Ofloxacin.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- LEVOFLOXACIN (UNII: 6GNT3Y5LMF)
- LEVOFLOXACIN ANHYDROUS (UNII: RIX4E89Y14) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)
- HYPROMELLOSE 2910 (5 MPA.S) (UNII: R75537T0T4)
- HYPROMELLOSE 2910 (6 MPA.S) (UNII: 0WZ8WG20P6)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)
- POLYETHYLENE GLYCOL 400 (UNII: B697894SGQ)
- POLYSORBATE 80 (UNII: 6OZP39ZG8H)
- TITANIUM DIOXIDE (UNII: 15FIX9V2JP)
- FERRIC OXIDE RED (UNII: 1K09F3G675)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 199884 - levoFLOXacin 250 MG Oral Tablet
- RxCUI: 199884 - levofloxacin 250 MG Oral Tablet
- RxCUI: 199884 - levofloxacin (as levofloxacin hemihydrate) 250 MG Oral Tablet
- RxCUI: 199885 - levoFLOXacin 500 MG Oral Tablet
- RxCUI: 199885 - levofloxacin 500 MG Oral Tablet
* Please review the full disclaimer at the bottom of this page.